Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Kymab Limited, a pioneering biopharmaceutical company headquartered in Great Britain, focuses on the development of innovative therapies for autoimmune diseases and cancer. Founded in 2010, Kymab has made significant strides in the biotechnology sector, particularly with its proprietary antibody platform, which enables the creation of unique monoclonal antibodies.
The company’s flagship product, KY1005, is designed to modulate immune responses, showcasing Kymab's commitment to addressing unmet medical needs. With a strong presence in both the UK and the US, Kymab has established itself as a key player in the biopharmaceutical industry, recognised for its cutting-edge research and development capabilities. Notable achievements include successful clinical trials and strategic partnerships that enhance its market position and drive future growth.
16
DitchCarbon score
-17 vs industry average
Kymab Limited’s score of 16 is lower than 46% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Kymab Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Medium
Research Services has typical carbon intensity
Industry performance
0.198
20182025
The Research Services industry has reduced its overall emissions by 19% since 2018
Reported emissions
No reported emissions data is available for Kymab Limited yet.
Kymab Limited's reported carbon emissions
Kymab Limited, headquartered in Great Britain, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary and may inherit climate-related data from its parent organization, but no specific details are provided regarding this cascade.
In terms of climate commitments, Kymab Limited has not outlined any reduction targets or initiatives, including those aligned with the Science Based Targets initiative (SBTi) or other industry standards. The lack of documented climate pledges suggests that the company may still be in the early stages of developing a comprehensive sustainability strategy.
As the industry increasingly prioritises carbon neutrality and climate action, Kymab Limited's future commitments and potential emissions data will be crucial for assessing its environmental impact and alignment with global climate goals.
Assessing Kymab Limited as a supplier or portfolio company?
- See verified emissions data for over 2 million organizations
- View emissions forecasts for Kymab Limited and the organizations you buy from or invest in
- Get PCAF data quality (DQ) scores, including for private organizations
Kymab Limited’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Kymab Limited yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives
Science Based Targets Initiative
Inherited from SanofiSee details
Active
Carbon Disclosure Project
Inherited from SanofiSign in to view
Active
The Climate Pledge
See details
Not active
UN Global Compact Climate Champions initiative
Inherited from SanofiSee details
Not active
RE 100
Inherited from SanofiSee details
Not active
Climate Action 100
See details
Not active
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Kymab Limited yet.
Need this data for financed emissions?
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more